These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
284 related articles for article (PubMed ID: 31958073)
1. Circulating Epstein-Barr virus microRNA profile reveals novel biomarker for nasopharyngeal carcinoma diagnosis. Wu L; Wang J; Zhu D; Zhang S; Zhou X; Zhu W; Zhu J; He X Cancer Biomark; 2020; 27(3):365-375. PubMed ID: 31958073 [TBL] [Abstract][Full Text] [Related]
2. Circulating Epstein-Barr virus microRNAs miR-BART7 and miR-BART13 as biomarkers for nasopharyngeal carcinoma diagnosis and treatment. Zhang G; Zong J; Lin S; Verhoeven RJ; Tong S; Chen Y; Ji M; Cheng W; Tsao SW; Lung M; Pan J; Chen H Int J Cancer; 2015 Mar; 136(5):E301-12. PubMed ID: 25213622 [TBL] [Abstract][Full Text] [Related]
3. Circulating Epstein-Barr virus microRNAs BART7-3p and BART13-3p as novel biomarkers in nasopharyngeal carcinoma. Lu T; Guo Q; Lin K; Chen H; Chen Y; Xu Y; Lin C; Su Y; Chen Y; Chen M; Zheng Y; Ye Y; Lin S; Zong J; Pan J Cancer Sci; 2020 May; 111(5):1711-1723. PubMed ID: 32155300 [TBL] [Abstract][Full Text] [Related]
4. Detection of Epstein-Barr virus (EBV)-encoded microRNAs in plasma of patients with nasopharyngeal carcinoma. Gao W; Wong TS; Lv KX; Zhang MJ; Tsang RK; Chan JY Head Neck; 2019 Mar; 41(3):780-792. PubMed ID: 30548946 [TBL] [Abstract][Full Text] [Related]
5. Systematic comparison of plasma EBV DNA, anti-EBV antibodies and miRNA levels for early detection and prognosis of nasopharyngeal carcinoma. Tan LP; Tan GW; Sivanesan VM; Goh SL; Ng XJ; Lim CS; Kim WR; Mohidin TBBM; Mohd Dali NS; Ong SH; Wong CY; Sawali H; Yap YY; Hassan F; Pua KC; Koay CE; Ng CC; Khoo AS; Int J Cancer; 2020 Apr; 146(8):2336-2347. PubMed ID: 31469434 [TBL] [Abstract][Full Text] [Related]
6. Identification of a 7-microRNA signature in plasma as promising biomarker for nasopharyngeal carcinoma detection. Zhang H; Zou X; Wu L; Zhang S; Wang T; Liu P; Zhu W; Zhu J Cancer Med; 2020 Feb; 9(3):1230-1241. PubMed ID: 31856390 [TBL] [Abstract][Full Text] [Related]
7. Vesicle-bound EBV-BART13-3p miRNA in circulation distinguishes nasopharyngeal from other head and neck cancer and asymptomatic EBV-infections. Ramayanti O; Verkuijlen SAWM; Novianti P; Scheepbouwer C; Misovic B; Koppers-Lalic D; van Weering J; Beckers L; Adham M; Martorelli D; Middeldorp JM; Pegtel DM Int J Cancer; 2019 May; 144(10):2555-2566. PubMed ID: 30411781 [TBL] [Abstract][Full Text] [Related]
8. Identification of two microRNA signatures in whole blood as novel biomarkers for diagnosis of nasopharyngeal carcinoma. Wen W; Mai SJ; Lin HX; Zhang MY; Huang JL; Hua X; Lin C; Long ZQ; Lu ZJ; Sun XQ; Liu SL; Yang Q; Zhu Q; Wang HY; Guo L J Transl Med; 2019 Jun; 17(1):186. PubMed ID: 31159814 [TBL] [Abstract][Full Text] [Related]
9. EBV-encoded miRNAs target ATM-mediated response in nasopharyngeal carcinoma. Lung RW; Hau PM; Yu KH; Yip KY; Tong JH; Chak WP; Chan AW; Lam KH; Lo AK; Tin EK; Chau SL; Pang JC; Kwan JS; Busson P; Young LS; Yap LF; Tsao SW; To KF; Lo KW J Pathol; 2018 Apr; 244(4):394-407. PubMed ID: 29230817 [TBL] [Abstract][Full Text] [Related]
10. Profiling of Epstein-Barr virus-encoded microRNAs in nasopharyngeal carcinoma reveals potential biomarkers and oncomirs. Wong AM; Kong KL; Tsang JW; Kwong DL; Guan XY Cancer; 2012 Feb; 118(3):698-710. PubMed ID: 21720996 [TBL] [Abstract][Full Text] [Related]
11. MicroRNA expression profiling analysis in serum for nasopharyngeal carcinoma diagnosis. Zou X; Zhu D; Zhang H; Zhang S; Zhou X; He X; Zhu J; Zhu W Gene; 2020 Feb; 727():144243. PubMed ID: 31743768 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of circulating EBV microRNA BART2-5p in facilitating early detection and screening of nasopharyngeal carcinoma. Jiang C; Chen J; Xie S; Zhang L; Xiang Y; Lung M; Kam NW; Kwong DL; Cao S; Guan XY Int J Cancer; 2018 Dec; 143(12):3209-3217. PubMed ID: 29971780 [TBL] [Abstract][Full Text] [Related]
13. Epstein-Barr virus mir-bart1-5p detection via nasopharyngeal brush sampling is effective for diagnosing nasopharyngeal carcinoma. Zheng XH; Lu LX; Cui C; Chen MY; Li XZ; Jia WH Oncotarget; 2016 Jan; 7(4):4972-80. PubMed ID: 26701721 [TBL] [Abstract][Full Text] [Related]
14. Epstein-Barr Virus DNA in Nasopharyngeal Carcinoma: A Brief Review. Xue F; He X Methods Mol Biol; 2020; 2204():99-107. PubMed ID: 32710318 [TBL] [Abstract][Full Text] [Related]
15. Plasma Epstein-Barr virus DNA and risk of nasopharyngeal carcinoma in a prospective seropositive population. Chen WJ; Xu WN; Wang HY; Chen XX; Li XQ; Xie SH; Lin DF; Cao SM BMC Cancer; 2021 Jun; 21(1):651. PubMed ID: 34074258 [TBL] [Abstract][Full Text] [Related]
16. miRNAs derived from circulating small extracellular vesicles as diagnostic biomarkers for nasopharyngeal carcinoma. Jiang L; Zhang Y; Li B; Kang M; Yang Z; Lin C; Hu K; Wei Z; Xu M; Mi J; Wang R; Wu F Cancer Sci; 2021 Jun; 112(6):2393-2404. PubMed ID: 33728743 [TBL] [Abstract][Full Text] [Related]
17. The diagnostic and prognostic values of plasma Epstein-Barr virus DNA for residual cervical lymphadenopathy in nasopharyngeal carcinoma patients: a retrospective study. Liu SL; Sun XS; Li XY; Tang LQ; Chen QY; Lin HX; Liang YJ; Yan JJ; Lin C; Guo SS; Liu LT; Li Y; Xie HJ; Tang QN; Liang H; Guo L; Mai HQ Cancer Commun (Lond); 2019 Mar; 39(1):14. PubMed ID: 30925939 [TBL] [Abstract][Full Text] [Related]
18. Prognostic values of the integrated model incorporating the volume of metastatic regional cervical lymph node and pretreatment serum Epstein-Barr virus DNA copy number in predicting distant metastasis in patients with N1 nasopharyngeal carcinoma. Yao JJ; Zhou GQ; Wang YQ; Wang SY; Zhang WJ; Jin YN; Zhang F; Li L; Liu LZ; Cheng ZB; Ma J; Qi ZY; Sun Y Chin J Cancer; 2017 Dec; 36(1):98. PubMed ID: 29284539 [TBL] [Abstract][Full Text] [Related]
19. Circulation EBV Mir-Bart-7 Relating to Clinical Manifestation in Nasopharyngeal Carcinoma. Wardana T; Gunawan L; Herawati C; Oktriani R; Anwar S; Astuti I; Aryandono T; Mubarika S Asian Pac J Cancer Prev; 2020 Sep; 21(9):2777-2782. PubMed ID: 32986380 [TBL] [Abstract][Full Text] [Related]
20. Targeting Epstein-Barr virus oncoprotein LMP1-mediated high oxidative stress suppresses EBV lytic reactivation and sensitizes tumors to radiation therapy. Hu J; Li Y; Li H; Shi F; Xie L; Zhao L; Tang M; Luo X; Jia W; Fan J; Zhou J; Gao Q; Qiu S; Wu W; Zhang X; Liao W; Bode AM; Cao Y Theranostics; 2020; 10(26):11921-11937. PubMed ID: 33204320 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]